{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:39:18Z","timestamp":1789547958911,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Genentech, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several bispecific antibodies (BsAbs), including mosunetuzumab, glofitamab, and epcoritamab, are approved for non-Hodgkin lymphoma (NHL). However, real-world patient-centered data evaluating treatment-related time burden and preferences are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an online survey of 120 patients with relapsed\/refractory follicular lymphoma (FL; N\u2009=\u200960) and diffuse large B-cell lymphoma (DLBCL; N\u2009=\u200960) receiving BsAbs. Participants reported all-cause healthcare visits and time spent on cancer-related healthcare resource utilization over the past 30\u2009days, including travel, treatment administration, recovery, and impact on daily activities. Participants also evaluated two hypothetical treatment profiles to assess preference for fixed-duration versus treat-to-progression therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants with FL reported a mean of 2.5 healthcare visits in the past 30\u2009days, with significantly fewer visits for mosunetuzumab versus epcoritamab (1.7 vs 3.3, respectively; P\u2009&amp;lt;\u2009.01). In DLBCL, the mean was 2.6 visits, with fewer visits for glofitamab versus epcoritamab (2.2 vs 3.0; P\u2009=.01). Although epcoritamab visits were shorter in FL, more frequent visits and longer recovery time resulted in significantly lower monthly time burden with mosunetuzumab versus epcoritamab (31.2 vs 61.9\u2009hours; P\u2009&amp;lt;\u2009.05). Similarly, monthly time burden was also lower with glofitamab than epcoritamab in DLBCL (43.0 vs 87.7\u2009hours; P\u2009&amp;lt;\u2009.05). Most participants reported little to moderate impact on daily activities. Across treatment groups, \u226592% preferred a hypothetical fixed-duration regimen over a treat-to-progression therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our real-world data, including novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphasize the importance of incorporating patient convenience and preference into shared decision-making in NHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag202","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:36:55Z","timestamp":1779190615000},"source":"Crossref","is-referenced-by-count":2,"title":["Patient-reported time toxicity with bispecific antibody therapies in relapsed\/refractory follicular lymphoma and diffuse large B-cell lymphoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-1335","authenticated-orcid":false,"given":"Ajay","family":"Major","sequence":"first","affiliation":[{"name":"University of Colorado School of Medicine Division of Hematology, , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[{"name":"Genentech, Inc ., South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Masaquel","sequence":"additional","affiliation":[{"name":"Genentech, Inc ., South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazie","family":"Tsang","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Hematology\/Oncology, Department of Medicine, , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center and University of Washington Department of Medicine, Divison of Hematology and Oncology, , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"UT Health San Antonio MD Anderson Cancer Center Department of Hematology and Oncology, , San Antonio, TX 78229,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Pophali","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Carbone Cancer Center Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, , Madison, WI 53792,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Werner","sequence":"additional","affiliation":[{"name":"Cancer Support Community , Washington, DC 20020,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bungay","sequence":"additional","affiliation":[{"name":"Analysis Group ULC , Toronto, ON M5X 1A9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latr\u00e9mouille-Viau","sequence":"additional","affiliation":[{"name":"Analysis Group ULC , Montreal, QC H3B 0G7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group ULC , Montreal, QC H3B 0G7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Reyes","sequence":"additional","affiliation":[{"name":"Genentech, Inc ., South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[{"name":"Genentech, Inc ., South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourenia","family":"Cassoli","sequence":"additional","affiliation":[{"name":"Genentech, Inc ., South San Francisco, CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center Department of Medicine, Division of Hematologic Malignancies, , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026061205562130500_oyag202-B1","author":"Food and Drug Administration"},{"key":"2026061205562130500_oyag202-B2","author":"Food and Drug Administration"},{"key":"2026061205562130500_oyag202-B3","author":"Food and Drug Administration"},{"key":"2026061205562130500_oyag202-B4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/jco.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026061205562130500_oyag202-B6","doi-asserted-by":"publisher","first-page":"e2447649","DOI":"10.1001\/jamanetworkopen.2024.47649","article-title":"Patient, caregiver, and clinician perspectives on the time burdens of cancer care","volume":"7","author":"Gupta","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026061205562130500_oyag202-B7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/oncolo\/oyae016","article-title":"Consuming patients\u2019 days: time spent on ambulatory appointments by people with cancer","volume":"29","author":"Kagalwalla","year":"2024","journal-title":"Oncologist"},{"key":"2026061205562130500_oyag202-B8","doi-asserted-by":"publisher","first-page":"e18198","DOI":"10.1200\/JCO.2019.37.15_suppl.e18198","article-title":"Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey","volume":"37","author":"Price","year":"2019","journal-title":"JCO"},{"key":"2026061205562130500_oyag202-B9","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1002\/onco.13721","article-title":"Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"key":"2026061205562130500_oyag202-B10","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1182\/blood-2024-208149","article-title":"Economic burden and patterns of care among patients with follicular lymphoma in the US: a retrospective claims analysis","volume":"144","author":"Garg","year":"2024","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B11","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2024-198476","article-title":"A healthcare utilization model comparing time toxicity between glofitamab and epcoritamab","volume":"144","author":"Torka","year":"2024","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B12","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jval.2025.04.323","article-title":"EE31 time burden of bispecific antibody (BsAb) options in relapsed or refractory (R\/R) follicular lymphoma (FL): Fixed-Duration mosunetuzumab versus treat to progression epcoritamab","volume":"28","author":"Ma","year":"2025","journal-title":"Value Health"},{"key":"2026061205562130500_oyag202-B13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1182\/blood-2024-198414","article-title":"Travel burden and travel costs of bispecific antibodies in patients with relapsed\/refractory diffuse large B-Cell lymphoma and relapsed\/refractory follicular lymphoma","volume":"144","author":"Huntington","year":"2024","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2024.02.013","article-title":"Financial toxicity, time toxicity, and quality of life in multiple myeloma","volume":"24","author":"Banerjee","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026061205562130500_oyag202-B15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.46883\/2021.25920935","article-title":"Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab","volume":"35","author":"Drill","year":"2021","journal-title":"Oncology (Williston Park)"},{"key":"2026061205562130500_oyag202-B16","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1080\/14796694.2024.2354157","article-title":"Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed\/refractory diffuse large B-cell lymphoma: an institutional perspective","volume":"20","author":"Lei","year":"2024","journal-title":"Future Oncology (London, England)"},{"key":"2026061205562130500_oyag202-B17","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","article-title":"Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m(2) vs. twice-weekly 27 mg\/m(2) carfilzomib (randomized A.R.R.O.W. study)","volume":"33","author":"Moreau","year":"2019","journal-title":"Leukemia"},{"key":"2026061205562130500_oyag202-B18","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2025-2622","article-title":"Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): a real-world study of medicare beneficiaries in the United States (US)","volume":"146","author":"Frosch","year":"2025","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B19","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1182\/blood-2024-198153","article-title":"CAR T cell therapy in early relapsed\/refractory large B-Cell lymphoma: real world analysis from the cell therapy consortium","volume":"144","author":"Rojek","year":"2024","journal-title":"Blood"},{"key":"2026061205562130500_oyag202-B20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026061205562130500_oyag202-B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"The Lancet"},{"key":"2026061205562130500_oyag202-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2025.16.7.19","article-title":"Operationalization and use of bispecific T-Cell-engaging antibodies in community practices: multidisciplinary perspectives on developing logistics and workflow for cytokine release syndrome management","author":"Donnellan","year":"2025","journal-title":"J Adv Pract Oncol"},{"key":"2026061205562130500_oyag202-B23","doi-asserted-by":"publisher","first-page":"e473916","DOI":"10.1200\/edbk-25-473916","article-title":"Easy as ABC: managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-Cell therapies","volume":"45","author":"Jain","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026061205562130500_oyag202-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2024.15.8.15","article-title":"Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination","author":"Mahmoudjafari","year":"2024","journal-title":"J Adv Pract Oncol"},{"key":"2026061205562130500_oyag202-B25","author":"Association of Cancer Care Centre"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag202\/68363908\/oyag202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag202\/68363908\/oyag202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag202\/68363908\/oyag202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:56:30Z","timestamp":1781258190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag202\/8690191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag202","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,21]]},"article-number":"oyag202"}}